Neurocrine Biosciences Stock Price, News & Analysis (NASDAQ:NBIX)

$80.68 2.12 (2.70 %)
(As of 01/22/2018 10:40 AM ET)
Previous Close$78.56
Today's Range$78.48 - $80.98
52-Week Range$38.43 - $83.84
Volume1.03 million shs
Average Volume1.10 million shs
Market Capitalization$7.14 billion
P/E Ratio-36.34
Dividend YieldN/A
Beta0.35

About Neurocrine Biosciences (NASDAQ:NBIX)

Neurocrine Biosciences logoNeurocrine Biosciences, Inc. is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson's disease. Its product pipeline also includes NBI-640756, which targets tremor and NBI-74788, which targets classic congenital adrenal hyperplasia. Its R&D focus is on addressing diseases and disorders of the central nervous and endocrine systems.

Receive NBIX News and Ratings via Email

Sign-up to receive the latest news and ratings for NBIX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:NBIX
CUSIP64125C10
Phone858-617-7600

Debt

Debt-to-Equity Ratio1.05%
Current Ratio14.38%
Quick Ratio14.37%

Price-To-Earnings

Trailing P/E Ratio-36.342178638835
Forward P/E Ratio-50.74
P/E Growth75.47

Sales & Book Value

Annual Sales$15 million
Price / Sales475.96
Cash FlowN/A
Price / CashN/A
Book Value$3.62 per share
Price / Book22.29

Profitability

Trailing EPS($2.22)
Net Income$-141,090,000.00
Net MarginsN/A
Return on Equity-61.88%
Return on Assets-35.60%

Miscellaneous

Employees196
Outstanding Shares88,490,000

Neurocrine Biosciences (NASDAQ:NBIX) Frequently Asked Questions

What is Neurocrine Biosciences' stock symbol?

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

How were Neurocrine Biosciences' earnings last quarter?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) announced its quarterly earnings data on Wednesday, November, 1st. The company reported ($0.13) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.49) by $0.36. The business earned $60.77 million during the quarter, compared to the consensus estimate of $29.38 million. During the same period last year, the company earned ($0.43) EPS. View Neurocrine Biosciences' Earnings History.

When will Neurocrine Biosciences make its next earnings announcement?

Neurocrine Biosciences is scheduled to release their next quarterly earnings announcement on Monday, February, 12th 2018. View Earnings Estimates for Neurocrine Biosciences.

Where is Neurocrine Biosciences' stock going? Where will Neurocrine Biosciences' stock price be in 2018?

17 equities research analysts have issued twelve-month price targets for Neurocrine Biosciences' stock. Their forecasts range from $55.00 to $109.00. On average, they expect Neurocrine Biosciences' stock price to reach $82.31 in the next twelve months. View Analyst Ratings for Neurocrine Biosciences.

What are Wall Street analysts saying about Neurocrine Biosciences stock?

Here are some recent quotes from research analysts about Neurocrine Biosciences stock:

  • 1. Needham & Company LLC analysts commented, "Neurocrine reported 3Q17 financial results yesterday. Ingrezza 3Q17 sales were $45.8M, well above our $20.0M and consensus $11M ests. Mgmt noted growth in TRX from 745 in 2Q17 to 5100 in 3Q17. We are raising our near-term and long-term sales ests significantly. Our 4Q17 Ingrezza sales estimate is $55.0M (was $15.0M). Mgmt highlighted possible challenges in 4Q17, including new competitor Austedo and essentially a reduction in price w/ introduction of 80mg capsule. Nevertheless, we believe our ests may still be conservative. Our new $86 price target (was $58) is 25x our $4.72 2020 EPS est, disc 15% annually." (11/2/2017)
  • 2. Cowen Inc analysts commented, "NBIX remains well funded, ending Q4 with $352MM in cash." (2/15/2017)
  • 3. Robert W. Baird analysts commented, "No change to outlook heading into Ingrezza approval. Neurocrine reported a solid end to the year, modestly beating estimates on lower-than-expected opex. Though we are only a few weeks into 2017, it has already been a busy year for NBIX. Expect the year to continue to bring multiple updates, from potential approval of Ingrezza in TD and Tourette data in May to Phase 3 UF data for elagolix near year-end, an elagolix NDA submission, advances in CAH and essential tremor, and FDA discussions on newly licensed opicapone' Earnings and spend in-line, expect accelerations into launch. 4Q16 EPS of ($0.51) modestly beat our/consensus estimates of ($0.54)/($0.57), respectively, due to lower than projected operating expenses. Looking ahead to 2017, management expects opex to increase to about $230M-$240M due activities surrounding the launch of Ingrezza." (2/15/2017)

Who are some of Neurocrine Biosciences' key competitors?

Who are Neurocrine Biosciences' key executives?

Neurocrine Biosciences' management team includes the folowing people:

  • William H. Rastetter Ph.D., Independent Chairman of the Board (Age 68)
  • Kevin C. Gorman Ph.D., Chief Executive Officer, Director (Age 58)
  • Matt Abernethy, Chief Financial Officer (Age 38)
  • Eric S. Benevich, Chief Commercial Officer (Age 51)
  • Haig P. Bozigian Ph.D., Chief Development Officer (Age 59)
  • Julie Cooke, Chief People Officer
  • Kyle Gano Ph.D., Chief Business Development Officer (Age 44)
  • Dimitri E. Grigoriadis Ph.D., Chief Research Officer (Age 59)
  • Malcolm Lloyd-Smith, Chief Regulatory Officer (Age 61)
  • Christopher F. O'Brien M.D., Chief Medical Officer (Age 60)

Who owns Neurocrine Biosciences stock?

Neurocrine Biosciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Schwab Charles Investment Management Inc. (0.46%), Frontier Capital Management Co. LLC (0.14%), GW&K Investment Management LLC (0.10%), Bank of Montreal Can (0.01%), State of Alaska Department of Revenue (0.01%) and Crow Point Partners LLC (0.00%). Company insiders that own Neurocrine Biosciences stock include Christopher Flint Obrien, Corinne H Nevinny, Darin Lippoldt, Dimitri E Grigoriadis, Gary A Lyons, Haig P Bozigian, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Richard F Pops, Timothy P Coughlin and William H Rastetter. View Institutional Ownership Trends for Neurocrine Biosciences.

Who bought Neurocrine Biosciences stock? Who is buying Neurocrine Biosciences stock?

Neurocrine Biosciences' stock was purchased by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Schwab Charles Investment Management Inc., GW&K Investment Management LLC, Bank of Montreal Can, State of Alaska Department of Revenue and Crow Point Partners LLC. View Insider Buying and Selling for Neurocrine Biosciences.

How do I buy Neurocrine Biosciences stock?

Shares of Neurocrine Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Neurocrine Biosciences' stock price today?

One share of Neurocrine Biosciences stock can currently be purchased for approximately $80.68.

How big of a company is Neurocrine Biosciences?

Neurocrine Biosciences has a market capitalization of $7.14 billion and generates $15 million in revenue each year. The company earns $-141,090,000.00 in net income (profit) each year or ($2.22) on an earnings per share basis. Neurocrine Biosciences employs 196 workers across the globe.

How can I contact Neurocrine Biosciences?

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company can be reached via phone at 858-617-7600 or via email at [email protected]


MarketBeat Community Rating for Neurocrine Biosciences (NBIX)

Community Ranking:  4.2 out of 5 (star star star star)
Outperform Votes:  589 (Vote Outperform)
Underperform Votes:  113 (Vote Underperform)
Total Votes:  702
MarketBeat's community ratings are surveys of what our community members think about Neurocrine Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Neurocrine Biosciences (NASDAQ:NBIX) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.002.942.94
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
17 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
17 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
16 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
16 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $82.31$78.88$68.81$67.69
Price Target Upside: 1.16% upside12.50% upside10.42% upside44.72% upside

Neurocrine Biosciences (NASDAQ:NBIX) Consensus Price Target History

Price Target History for Neurocrine Biosciences (NASDAQ:NBIX)

Neurocrine Biosciences (NASDAQ:NBIX) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/16/2018Needham & Company LLCBoost Price TargetBuy$95.00HighView Rating Details
1/15/2018OppenheimerSet Price TargetBuy$85.00 -> $95.00HighView Rating Details
1/5/2018Jefferies GroupBoost Price TargetBuy$105.00MediumView Rating Details
11/3/2017Robert W. BairdReiterated RatingBuy$84.00N/AView Rating Details
11/2/2017BarclaysBoost Price TargetOverweight$75.00 -> $85.00N/AView Rating Details
11/2/2017Deutsche BankReiterated RatingBuy$79.00N/AView Rating Details
11/2/2017BMO Capital MarketsBoost Price TargetPositive -> Outperform$83.00 -> $109.00N/AView Rating Details
11/2/2017Leerink SwannReiterated RatingOutperform$72.00 -> $83.00N/AView Rating Details
11/2/2017CitigroupReiterated RatingBuy$79.00N/AView Rating Details
10/25/2017Piper Jaffray CompaniesReiterated RatingBuy$76.00N/AView Rating Details
8/9/2017CowenReiterated RatingOutperform$60.00 -> $65.00MediumView Rating Details
5/24/2017JPMorgan Chase & Co.Set Price TargetBuy$57.00MediumView Rating Details
5/15/2017Bank of AmericaReiterated RatingBuy$70.00MediumView Rating Details
3/7/2017Cantor FitzgeraldReiterated RatingOverweight$80.00N/AView Rating Details
2/16/2017HC WainwrightBoost Price TargetPositive$80.00 -> $100.00N/AView Rating Details
2/10/2017ICAPReiterated RatingOutperform$55.00N/AView Rating Details
1/27/2017CIBCUpgradeMarket Perform -> OutperformN/AView Rating Details
(Data available from 1/22/2016 forward)

Earnings

Neurocrine Biosciences (NASDAQ:NBIX) Earnings History and Estimates Chart

Earnings by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Neurocrine Biosciences (NASDAQ NBIX) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/12/2018($0.10)N/AView Earnings Details
11/1/2017Q3 2017($0.49)($0.13)$29.38 million$60.77 millionViewN/AView Earnings Details
8/3/2017Q2 17($0.67)($0.68)$0.61 million$6.34 millionViewListenView Earnings Details
5/9/2017Q1 17($0.67)($0.90)$3.00 millionViewListenView Earnings Details
2/14/2017Q416($0.55)($0.51)$4.55 millionViewListenView Earnings Details
11/2/2016Q316($0.57)($0.43)ViewN/AView Earnings Details
8/3/2016Q2 2016($0.50)($0.46)ViewN/AView Earnings Details
5/5/2016Q1($0.29)($0.22)$15.43 million$15.00 millionViewN/AView Earnings Details
2/11/2016Q415($0.32)($0.34)$3.33 millionViewListenView Earnings Details
10/29/2015Q315($0.25)($0.40)$6.66 millionViewListenView Earnings Details
7/29/2015Q2($0.29)($0.28)$0.41 millionViewListenView Earnings Details
4/30/2015Q115($0.30)($0.01)$19.76 millionViewN/AView Earnings Details
2/9/2015Q414($0.24)($0.26)ViewN/AView Earnings Details
11/3/2014Q314($0.21)($0.21)ViewN/AView Earnings Details
8/6/2014Q214($0.18)($0.18)$0.12 millionViewN/AView Earnings Details
4/30/2014Q114($0.19)($0.17)$0.78 millionViewN/AView Earnings Details
2/6/2014Q413($0.17)($0.16)$0.79 million$0.73 millionViewN/AView Earnings Details
10/29/2013Q313($0.20)($0.17)$0.79 million$0.73 millionViewN/AView Earnings Details
7/25/2013Q2 2013($0.20)($0.18)$0.77 million$0.73 millionViewListenView Earnings Details
5/2/2013Q1 2013($0.18)($0.18)$1.07 million$0.70 millionViewListenView Earnings Details
2/8/2013Q4 2012($0.08)$0.14$9.43 million$21.90 millionViewListenView Earnings Details
10/31/2012Q312($0.05)($0.05)$10.28 million$9.40 millionViewN/AView Earnings Details
7/31/2012($0.03)($0.01)ViewN/AView Earnings Details
5/2/2012($0.01)ViewN/AView Earnings Details
2/8/2012Q4 2011$0.01$0.02ViewN/AView Earnings Details
10/31/2011$0.19$0.56ViewN/AView Earnings Details
7/28/2011$0.04$0.04ViewN/AView Earnings Details
5/3/2011$0.05$0.05ViewN/AView Earnings Details
2/10/2011$0.04$0.05ViewN/AView Earnings Details
10/28/2010Q3 2010$0.05$0.06ViewN/AView Earnings Details
7/28/2010Q2 2010($0.17)($0.09)ViewN/AView Earnings Details
4/28/2010Q1 2010($0.24)($0.20)ViewN/AView Earnings Details
2/3/2010Q4 2009($0.28)($0.22)ViewN/AView Earnings Details
10/28/2009Q3 2009($0.35)($0.21)ViewN/AView Earnings Details
7/29/2009Q2 2009($0.41)($0.37)ViewN/AView Earnings Details
5/5/2009Q1 2009($0.38)($0.38)ViewN/AView Earnings Details
2/3/2009Q4 2008($0.47)($0.75)ViewN/AView Earnings Details
10/28/2008Q3 2008($0.52)($0.46)ViewN/AView Earnings Details
7/30/2008Q2 2008($0.52)($0.55)ViewN/AView Earnings Details
4/30/2008Q1 2008($0.54)($0.55)ViewN/AView Earnings Details
2/5/2008Q4 2007($0.84)($0.71)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Neurocrine Biosciences (NASDAQ:NBIX) Earnings Estimates

2018 EPS Consensus Estimate: $0.42
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183($0.26)($0.07)($0.16)
Q2 20183$0.02$0.25$0.10
Q3 20183($0.13)$0.31$0.15
Q4 20183($0.13)$0.95$0.33
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Neurocrine Biosciences (NASDAQ:NBIX)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Neurocrine Biosciences (NASDAQ NBIX) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.80%
Insider Trades by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)
Institutional Ownership by Quarter for Neurocrine Biosciences (NASDAQ:NBIX)

Neurocrine Biosciences (NASDAQ NBIX) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/28/2018Darin LippoldtInsiderSell15,237$75.00$1,142,775.0028,394View SEC Filing  
1/16/2018Haig P BozigianInsiderSell1,625$79.12$128,570.00View SEC Filing  
1/16/2018Kevin Charles GormanCEOSell3,750$78.89$295,837.50View SEC Filing  
1/3/2018Darin LippoldtInsiderSell1,979$79.36$157,053.44View SEC Filing  
12/28/2017Darin LippoldtInsiderSell15,237$75.00$1,142,775.00View SEC Filing  
12/8/2017Darin LippoldtInsiderSell2,955$75.00$221,625.0016,112View SEC Filing  
12/4/2017Darin LippoldtInsiderSell6,279$75.04$471,176.1619,436View SEC Filing  
12/1/2017Gary A LyonsDirectorSell10,000$72.92$729,200.00272,066View SEC Filing  
11/15/2017Darin LippoldtInsiderSell9,900$73.05$723,195.00View SEC Filing  
11/8/2017Dimitri E GrigoriadisInsiderSell30,000$74.58$2,237,400.0077,691View SEC Filing  
11/2/2017Kyle GanoInsiderSell24,818$71.05$1,763,318.9084,596View SEC Filing  
10/2/2017Christopher Flint ObrienInsiderSell6,925$61.04$422,702.0055,898View SEC Filing  
9/6/2017Haig P BozigianInsiderSell26,250$60.00$1,575,000.00144,601View SEC Filing  
9/5/2017Christopher Flint ObrienInsiderSell52,817$57.50$3,036,977.50101,790View SEC Filing  
8/9/2017Dimitri E GrigoriadisInsiderSell15,354$55.00$844,470.00123,045View SEC Filing  
8/4/2017Haig P BozigianInsiderSell22,500$50.00$1,125,000.00154,601View SEC Filing  
7/27/2017Christopher Flint ObrienInsiderSell8,734$50.00$436,700.0057,707View SEC Filing  
5/23/2017Dimitri E GrigoriadisInsiderSell10,000$53.39$533,900.00107,691View SEC Filing  
5/19/2017Malcolm Lloyd-SmithInsiderSell9,960$53.63$534,154.8017,997View SEC Filing  
5/5/2017Corinne H NevinnyDirectorSell5,000$53.98$269,900.0034,603View SEC Filing  
5/2/2017Dimitri E GrigoriadisInsiderSell10,000$55.00$550,000.00117,691View SEC Filing  
5/2/2017Kevin Charles GormanCEOSell21,739$53.23$1,157,166.97354,346View SEC Filing  
5/1/2017Kyle GanoInsiderSell15,000$54.00$810,000.0088,246View SEC Filing  
4/12/2017Haig P BozigianInsiderSell13,065$50.42$658,737.30129,805View SEC Filing  
4/12/2017Kevin Charles GormanCEOSell19,596$50.42$988,030.32332,913View SEC Filing  
2/7/2017Malcolm Lloyd-SmithInsiderSell116$44.61$5,174.76View SEC Filing  
2/6/2017Dimitri E GrigoriadisInsiderSell727$43.13$31,355.51115,756View SEC Filing  
2/6/2017Kevin Charles GormanCEOSell3,010$43.18$129,971.80250,542View SEC Filing  
2/6/2017Timothy P CoughlinCFOSell963$43.14$41,543.82137,961View SEC Filing  
2/3/2017Christopher Flint ObrienInsiderSell1,500$42.50$63,750.0035,044View SEC Filing  
2/3/2017Kevin Charles GormanCEOSell3,125$42.55$132,968.75247,802View SEC Filing  
2/1/2017William H RastetterDirectorSell10,750$42.28$454,510.0025,000View SEC Filing  
1/17/2017Haig P BozigianInsiderSell1,625$40.63$66,023.75114,704View SEC Filing  
1/17/2017Kevin Charles GormanCEOSell3,750$40.65$152,437.50244,677View SEC Filing  
1/17/2017Timothy P CoughlinCFOSell1,750$40.65$71,137.50134,824View SEC Filing  
1/10/2017Christopher Flint ObrienInsiderSell1,750$43.35$75,862.5031,794View SEC Filing  
1/10/2017Kevin Charles GormanCEOSell3,750$43.28$162,300.00240,927View SEC Filing  
11/15/2016Christopher Flint ObrienInsiderSell25,000$52.84$1,321,000.0030,044View SEC Filing  
9/1/2016Malcolm Lloyd-SmithInsiderSell9,000$50.00$450,000.009,000View SEC Filing  
8/15/2016Christopher Flint ObrienInsiderSell12,500$48.73$609,125.0055,044View SEC Filing  
8/8/2016Corinne H NevinnyDirectorSell5,000$48.54$242,700.0025,555View SEC Filing  
5/25/2016Richard F PopsDirectorSell15,000$46.72$700,800.0015,464View SEC Filing  
5/16/2016Christopher Flint ObrienInsiderSell25,000$45.00$1,125,000.0080,044View SEC Filing  
4/11/2016Kyle GanoInsiderSell41,770$44.02$1,838,715.4057,788View SEC Filing  
4/6/2016Christopher Flint ObrienInsiderSell25,000$45.00$1,125,000.00105,044View SEC Filing  
2/3/2016Haig P BozigianInsiderSell1,375$38.13$52,428.75111,454View SEC Filing  
2/3/2016Kevin Charles GormanCEOSell3,125$38.04$118,875.00228,077View SEC Filing  
2/3/2016Timothy P CoughlinCFOSell1,500$38.06$57,090.00131,374View SEC Filing  
1/19/2016Haig P BozigianInsiderSell1,625$46.77$76,001.25110,079View SEC Filing  
1/19/2016Kevin Charles GormanCEOSell3,750$46.70$175,125.00224,952View SEC Filing  
1/19/2016Timothy P CoughlinCFOSell1,750$46.69$81,707.50129,874View SEC Filing  
1/11/2016Haig P BozigianInsiderSell1,625$44.25$71,906.25108,454View SEC Filing  
1/11/2016Kevin Charles GormanCEOSell3,750$44.17$165,637.50221,202View SEC Filing  
1/11/2016Timothy P CoughlinCFOSell1,750$44.25$77,437.50128,124View SEC Filing  
11/27/2015Dimitri E. GrigoriadisinsiderSell10,000$57.50$575,000.00105,308View SEC Filing  
11/9/2015Darin LippoldtinsiderSell23,761$52.92$1,257,432.12View SEC Filing  
10/16/2015Haig P BozigianInsiderSell25,000$47.78$1,194,500.00106,829View SEC Filing  
10/16/2015Kevin Charles GormanCEOSell33,500$47.77$1,600,295.00217,452View SEC Filing  
9/18/2015Gary A. LyonsDirectorSell15,000$54.89$823,350.00252,066View SEC Filing  
7/20/2015Dimitri E GrigoriadisInsiderSell19,646$55.00$1,080,530.00View SEC Filing  
7/20/2015Timothy P CoughlinCFOSell20,000$55.00$1,100,000.00View SEC Filing  
7/13/2015Dimitri E GrigoriadisInsiderSell10,000$50.00$500,000.00View SEC Filing  
7/13/2015Timothy P CoughlinCFOSell20,000$50.00$1,000,000.00View SEC Filing  
6/23/2015W Thomas MitchellDirectorSell15,000$49.35$740,250.00View SEC Filing  
6/8/2015Christopher Flint ObrienInsiderSell10,000$45.00$450,000.00View SEC Filing  
6/8/2015Timothy P CoughlinCFOSell60,000$45.08$2,704,800.00View SEC Filing  
3/24/2015Gary A LyonsDirectorSell30,000$41.53$1,245,900.00View SEC Filing  
3/24/2015Kevin Charles GormanCEOSell40,000$41.53$1,661,200.00View SEC Filing  
2/10/2015Dimitri E GrigoriadisInsiderSell20,000$35.00$700,000.00View SEC Filing  
1/16/2015Christopher Flint ObrienInsiderSell1,750$30.79$53,882.50View SEC Filing  
1/16/2015Kevin Charles GormanCEOSell3,750$30.79$115,462.50View SEC Filing  
1/12/2015Kevin Charles GormanCEOSell3,750$28.43$106,612.50View SEC Filing  
1/12/2015Kyle GanoInsiderSell1,250$28.41$35,512.50View SEC Filing  
1/12/2015Timothy P CoughlinCFOSell1,750$28.37$49,647.50View SEC Filing  
1/8/2015Dimitri E GrigoriadisInsiderSell30,000$27.35$820,500.00View SEC Filing  
1/8/2015Kevin Charles GormanCEOSell25,000$27.39$684,750.00View SEC Filing  
1/8/2015Timothy P CoughlinCFOSell10,000$27.25$272,500.00View SEC Filing  
1/5/2015Dimitri E GrigoriadisInsiderSell2,500$22.76$56,900.00View SEC Filing  
1/2/2015W Thomas MitchellDirectorSell8,000$22.79$182,320.00View SEC Filing  
12/19/2014Christopher Flint ObrienInsiderSell20,000$24.02$480,400.00View SEC Filing  
12/19/2014Kevin Charles GormanCEOSell70,000$23.41$1,638,700.00View SEC Filing  
12/19/2014Timothy P CoughlinCFOSell30,000$23.46$703,800.00View SEC Filing  
12/17/2014Kyle GanoInsiderSell4,957$22.50$111,532.50View SEC Filing  
12/15/2014Dimitri E GrigoriadisInsiderSell12,794$22.35$285,945.90View SEC Filing  
12/12/2014Kyle GanoInsiderSell4,043$22.50$90,967.50View SEC Filing  
12/11/2014Christopher Flint ObrienInsiderSell40,000$21.82$872,800.00View SEC Filing  
12/10/2014Timothy P CoughlinCFOSell20,000$21.48$429,600.00View SEC Filing  
12/10/2014W Thomas MitchellDirectorSell7,000$21.90$153,300.00View SEC Filing  
11/28/2014Timothy P CoughlinCFOSell10,000$20.14$201,400.00View SEC Filing  
11/24/2014Christopher Flint ObrienInsiderSell5,463$19.53$106,692.39View SEC Filing  
10/31/2014Timothy P CoughlinCFOSell10,000$19.00$190,000.00View SEC Filing  
10/30/2014Timothy P CoughlinCFOSell20,000$18.31$366,200.00View SEC Filing  
10/1/2014W Thomas MitchellDirectorSell1,275$15.50$19,762.50View SEC Filing  
9/15/2014Gary A LyonsDirectorSell20,000$15.66$313,200.00View SEC Filing  
1/17/2014Dimitri GrigoriadisInsiderSell25,000$20.00$500,000.0077,058View SEC Filing  
1/10/2014Christopher Flint ObrienInsiderSell6,750$18.88$127,440.0096,544View SEC Filing  
1/10/2014Kevin Charles GormanCEOSell3,750$18.57$69,637.50180,952View SEC Filing  
1/10/2014Timothy CoughlinCFOSell1,750$18.56$32,480.0097,874View SEC Filing  
1/7/2014Dimitri GrigoriadisInsiderSell25,000$17.50$437,500.0075,433View SEC Filing  
1/7/2014Kevin Charles GormanCEOSell108,000$16.76$1,810,080.00177,202View SEC Filing  
1/7/2014Timothy CoughlinCFOSell70,000$16.75$1,172,500.0096,124View SEC Filing  
9/4/2013Kyle GanoInsiderSell2,400$15.61$37,464.0022,488View SEC Filing  
9/3/2013Christopher Flint ObrienInsiderSell5,000$16.00$80,000.0094,794View SEC Filing  
8/21/2013Haig BozigianInsiderSell13,999$15.04$210,544.9676,954View SEC Filing  
8/21/2013Timothy CoughlinCFOSell19,035$15.05$286,476.7596,124View SEC Filing  
8/6/2013W Thomas MitchellDirectorSell1,531$14.70$22,505.701,000View SEC Filing  
8/5/2013Haig BozigianInsiderSell11,001$15.00$165,015.0076,954View SEC Filing  
8/5/2013Timothy CoughlinCFOSell10,965$14.99$164,365.3596,124View SEC Filing  
7/12/2013Christopher Flint ObrienInsiderSell5,000$14.50$72,500.00View SEC Filing  
6/28/2013Christopher Flint ObrienInsiderSell11,357$13.33$151,388.81View SEC Filing  
6/27/2013Haig P BozigianInsiderSell8,000$13.00$104,000.00View SEC Filing  
6/21/2013Dimitri E GrigoriadisInsiderSell46,837$12.51$585,930.87View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Neurocrine Biosciences (NASDAQ NBIX) News Headlines

Source:
DateHeadline
$94.00 Million in Sales Expected for Neurocrine Biosciences, Inc. (NBIX) This Quarter$94.00 Million in Sales Expected for Neurocrine Biosciences, Inc. (NBIX) This Quarter
www.americanbankingnews.com - January 22 at 2:32 AM
 Analysts Anticipate Neurocrine Biosciences, Inc. (NBIX) to Announce $0.11 EPS Analysts Anticipate Neurocrine Biosciences, Inc. (NBIX) to Announce $0.11 EPS
www.americanbankingnews.com - January 20 at 11:26 PM
Neurocrine Biosciences, Inc. (NBIX) Insider Haig P. Bozigian Sells 1,625 SharesNeurocrine Biosciences, Inc. (NBIX) Insider Haig P. Bozigian Sells 1,625 Shares
www.americanbankingnews.com - January 18 at 7:58 PM
Neurocrine Biosciences, Inc. (NBIX) CEO Kevin Charles Gorman Sells 3,750 SharesNeurocrine Biosciences, Inc. (NBIX) CEO Kevin Charles Gorman Sells 3,750 Shares
www.americanbankingnews.com - January 18 at 7:34 PM
FY2017 EPS Estimates for Neurocrine Biosciences, Inc. (NBIX) Increased by AnalystFY2017 EPS Estimates for Neurocrine Biosciences, Inc. (NBIX) Increased by Analyst
www.americanbankingnews.com - January 18 at 6:44 AM
Neurocrine Biosciences, Inc. (NBIX) Forecasted to Post Q1 2018 Earnings of ($0.16) Per ShareNeurocrine Biosciences, Inc. (NBIX) Forecasted to Post Q1 2018 Earnings of ($0.16) Per Share
www.americanbankingnews.com - January 17 at 12:00 PM
Neurocrine Biosciences, Inc. (NBIX) Given Average Rating of "Buy" by AnalystsNeurocrine Biosciences, Inc. (NBIX) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - January 15 at 1:38 AM
Neurocrine, Ingrezza Sail Into 2018 - Seeking AlphaNeurocrine, Ingrezza Sail Into 2018 - Seeking Alpha
seekingalpha.com - January 11 at 10:13 AM
FY2017 EPS Estimates for Neurocrine Biosciences, Inc. Increased by Leerink Swann (NBIX)FY2017 EPS Estimates for Neurocrine Biosciences, Inc. Increased by Leerink Swann (NBIX)
www.americanbankingnews.com - January 10 at 6:56 AM
CELG Makes Blockbuster Purchase, MDXG, NBIX On Watch, Busy Year Ahead For ALNY - NasdaqCELG Makes Blockbuster Purchase, MDXG, NBIX On Watch, Busy Year Ahead For ALNY - Nasdaq
www.nasdaq.com - January 8 at 9:30 AM
Neurocrine Biosciences (NBIX) Appooints Eiry W. Roberts M.D. as ... - StreetInsider.comNeurocrine Biosciences (NBIX) Appooints Eiry W. Roberts M.D. as ... - StreetInsider.com
www.streetinsider.com - January 8 at 9:30 AM
Should You Be Concerned About Neurocrine Biosciences Inc’s (NASDAQ:NBIX) -54.35% Earnings Decline?Should You Be Concerned About Neurocrine Biosciences Inc’s (NASDAQ:NBIX) -54.35% Earnings Decline?
finance.yahoo.com - January 8 at 9:30 AM
Brokers Set Expectations for Neurocrine Biosciences, Inc.s Q1 2018 Earnings (NBIX)Brokers Set Expectations for Neurocrine Biosciences, Inc.'s Q1 2018 Earnings (NBIX)
www.americanbankingnews.com - January 8 at 5:02 AM
Neurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2017 Sales Results and 2018 Program MilestonesNeurocrine Biosciences Provides Preliminary Fourth Quarter and Full-Year 2017 Sales Results and 2018 Program Milestones
www.prnewswire.com - January 7 at 2:10 PM
Neurocrine Biosciences Announces Retirement of Christopher OBrien, M.D., and Appointment of Eiry W. Roberts, M.D., as Chief Medical OfficerNeurocrine Biosciences Announces Retirement of Christopher O'Brien, M.D., and Appointment of Eiry W. Roberts, M.D., as Chief Medical Officer
www.prnewswire.com - January 7 at 2:10 PM
$75.70 Million in Sales Expected for Neurocrine Biosciences, Inc. (NBIX) This Quarter$75.70 Million in Sales Expected for Neurocrine Biosciences, Inc. (NBIX) This Quarter
www.americanbankingnews.com - January 6 at 7:00 AM
Neurocrine Biosciences (NBIX) PT Raised to $105.00Neurocrine Biosciences (NBIX) PT Raised to $105.00
www.americanbankingnews.com - January 5 at 7:32 PM
Neurocrine Biosciences, Inc. (NBIX) Insider Sells $157,053.44 in StockNeurocrine Biosciences, Inc. (NBIX) Insider Sells $157,053.44 in Stock
www.americanbankingnews.com - January 4 at 7:56 PM
Neurocrine Biosciences, Inc. (NBIX) Expected to Post Earnings of $0.05 Per ShareNeurocrine Biosciences, Inc. (NBIX) Expected to Post Earnings of $0.05 Per Share
www.americanbankingnews.com - January 4 at 3:30 AM
Neurocrine Biosciences, Inc. (NBIX) Insider Darin Lippoldt Sells 15,237 SharesNeurocrine Biosciences, Inc. (NBIX) Insider Darin Lippoldt Sells 15,237 Shares
www.americanbankingnews.com - January 2 at 6:32 PM
Insider Selling: Neurocrine Biosciences, Inc. (NBIX) Insider Sells 15,237 Shares of StockInsider Selling: Neurocrine Biosciences, Inc. (NBIX) Insider Sells 15,237 Shares of Stock
www.americanbankingnews.com - January 2 at 6:32 PM
Neurocrine Biosciences to Present at the 36th Annual J.P. Morgan Healthcare ConferenceNeurocrine Biosciences to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 2 at 6:02 PM
Analyzing Neurocrine Biosciences (NBIX) & Auris Medical (EARS)Analyzing Neurocrine Biosciences (NBIX) & Auris Medical (EARS)
www.americanbankingnews.com - January 2 at 12:18 PM
Neurocrine Biosciences Sees Unusually Large Options Volume (NBIX)Neurocrine Biosciences Sees Unusually Large Options Volume (NBIX)
www.americanbankingnews.com - January 1 at 2:28 AM
Is Neurocrine Biosciences Inc’s (NASDAQ:NBIX) Balance Sheet A Threat To Its Future?Is Neurocrine Biosciences Inc’s (NASDAQ:NBIX) Balance Sheet A Threat To Its Future?
finance.yahoo.com - December 29 at 10:23 AM
Neurocrine Biosciences, Inc. (NBIX) Receives Average Recommendation of "Buy" from BrokeragesNeurocrine Biosciences, Inc. (NBIX) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - December 21 at 2:04 AM
 Brokerages Anticipate Neurocrine Biosciences, Inc. (NBIX) Will Announce Earnings of -$0.03 Per Share Brokerages Anticipate Neurocrine Biosciences, Inc. (NBIX) Will Announce Earnings of -$0.03 Per Share
www.americanbankingnews.com - December 18 at 11:47 AM
Neurocrine Biosciences (NBIX) PT Set at $85.00 by OppenheimerNeurocrine Biosciences (NBIX) PT Set at $85.00 by Oppenheimer
www.americanbankingnews.com - December 17 at 10:08 AM
Neurocrine Biosciences, Inc. (NBIX) Insider Sells $221,625.00 in StockNeurocrine Biosciences, Inc. (NBIX) Insider Sells $221,625.00 in Stock
www.americanbankingnews.com - December 11 at 5:58 PM
Neurocrine Biosciences to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare ConferenceNeurocrine Biosciences to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference
finance.yahoo.com - December 7 at 5:19 PM
Insider Selling: Neurocrine Biosciences, Inc. (NBIX) Insider Sells 6,279 Shares of StockInsider Selling: Neurocrine Biosciences, Inc. (NBIX) Insider Sells 6,279 Shares of Stock
www.americanbankingnews.com - December 6 at 5:46 PM
Neurocrine Biosciences, Inc. (NBIX) Director Sells $729,200.00 in StockNeurocrine Biosciences, Inc. (NBIX) Director Sells $729,200.00 in Stock
www.americanbankingnews.com - December 5 at 6:20 PM
Neurocrine Biosciences (NBIX) Presents Long-term Data Analyses ... - StreetInsider.comNeurocrine Biosciences (NBIX) Presents Long-term Data Analyses ... - StreetInsider.com
www.streetinsider.com - December 5 at 10:36 AM
Neurocrine Biosciences Presents Long-term Data Analyses from Open-label KINECT 4 Phase III Study Demonstrating INGREZZA® Improves Tardive Dyskinesia SymptomsNeurocrine Biosciences Presents Long-term Data Analyses from Open-label KINECT 4 Phase III Study Demonstrating INGREZZA® Improves Tardive Dyskinesia Symptoms
finance.yahoo.com - December 4 at 4:57 PM
 Analysts Expect Neurocrine Biosciences, Inc. (NBIX) Will Post Earnings of -$0.03 Per Share Analysts Expect Neurocrine Biosciences, Inc. (NBIX) Will Post Earnings of -$0.03 Per Share
www.americanbankingnews.com - November 30 at 9:26 AM
Neurocrine Biosciences to Present New Long-Term Data Evaluating INGREZZA® for the Treatment of Tardive Dyskinesia at the American College of Neuropsychopharmacology Annual MeetingNeurocrine Biosciences to Present New Long-Term Data Evaluating INGREZZA® for the Treatment of Tardive Dyskinesia at the American College of Neuropsychopharmacology Annual Meeting
finance.yahoo.com - November 29 at 5:18 PM
Neurocrine Biosciences, Inc. (NBIX) Receives Average Recommendation of "Buy" from AnalystsNeurocrine Biosciences, Inc. (NBIX) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 26 at 1:38 AM
Neurocrine Biosciences to Present at the 29th Annual Piper Jaffray Healthcare Conference - PR Newswire (press release)Neurocrine Biosciences to Present at the 29th Annual Piper Jaffray Healthcare Conference - PR Newswire (press release)
www.prnewswire.com - November 23 at 5:23 PM
Neurocrine Biosciences to Present at the 29th Annual Piper Jaffray Healthcare ConferenceNeurocrine Biosciences to Present at the 29th Annual Piper Jaffray Healthcare Conference
finance.yahoo.com - November 22 at 6:05 AM
Neurocrine Biosciences (NBIX) Names Matt Abernethy as CFONeurocrine Biosciences (NBIX) Names Matt Abernethy as CFO
www.streetinsider.com - November 21 at 8:31 AM
Detailed Research: Economic Perspectives on Nexstar Broadcasting Group, CECO Environmental, Performance Food Group, Neurocrine Biosciences, e.l.f. Beauty, and Big Lots — What Drives Growth in Todays Competitive LandscapeDetailed Research: Economic Perspectives on Nexstar Broadcasting Group, CECO Environmental, Performance Food Group, Neurocrine Biosciences, e.l.f. Beauty, and Big Lots — What Drives Growth in Today's Competitive Landscape
finance.yahoo.com - November 21 at 8:31 AM
Neurocrine Biosciences Appoints Matt Abernethy as Chief Financial OfficerNeurocrine Biosciences Appoints Matt Abernethy as Chief Financial Officer
www.prnewswire.com - November 20 at 4:23 PM
Head to Head Survey: Neurocrine Biosciences (NBIX) and Its CompetitorsHead to Head Survey: Neurocrine Biosciences (NBIX) and Its Competitors
www.americanbankingnews.com - November 18 at 5:12 AM
Neurocrine Biosciences, Inc. (NBIX) Insider Sells $723,195.00 in StockNeurocrine Biosciences, Inc. (NBIX) Insider Sells $723,195.00 in Stock
www.americanbankingnews.com - November 17 at 8:11 PM
Head-To-Head Comparison: Neurocrine Biosciences (NBIX) vs. Its CompetitorsHead-To-Head Comparison: Neurocrine Biosciences (NBIX) vs. Its Competitors
www.americanbankingnews.com - November 17 at 8:36 AM
Neurocrine Announces Long-Term Results Evaluating INGREZZA® for the Treatment of Adults with Tardive Dyskinesia Published in the Journal of Clinical PsychiatryNeurocrine Announces Long-Term Results Evaluating INGREZZA® for the Treatment of Adults with Tardive Dyskinesia Published in the Journal of Clinical Psychiatry
finance.yahoo.com - November 14 at 3:34 PM
Neurocrine Biosciences, Inc. (NBIX) Given a $85.00 Price Target by Oppenheimer Holdings, Inc. AnalystsNeurocrine Biosciences, Inc. (NBIX) Given a $85.00 Price Target by Oppenheimer Holdings, Inc. Analysts
www.americanbankingnews.com - November 14 at 3:18 PM
Dimitri E. Grigoriadis Sells 30,000 Shares of Neurocrine Biosciences, Inc. (NBIX) StockDimitri E. Grigoriadis Sells 30,000 Shares of Neurocrine Biosciences, Inc. (NBIX) Stock
www.americanbankingnews.com - November 13 at 4:48 PM
Zacks: Analysts Expect Neurocrine Biosciences, Inc. (NBIX) Will Post Quarterly Sales of $75.70 MillionZacks: Analysts Expect Neurocrine Biosciences, Inc. (NBIX) Will Post Quarterly Sales of $75.70 Million
www.americanbankingnews.com - November 13 at 4:46 AM
INGREZZA®, First FDA Approved Product for the Treatment of Tardive Dyskinesia, Receives Outstanding Therapeutic Product Award from Prestigious California Life Sciences AssociationINGREZZA®, First FDA Approved Product for the Treatment of Tardive Dyskinesia, Receives Outstanding Therapeutic Product Award from Prestigious California Life Sciences Association
finance.yahoo.com - November 12 at 10:12 AM

SEC Filings

Neurocrine Biosciences (NASDAQ:NBIX) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Neurocrine Biosciences (NASDAQ:NBIX) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Neurocrine Biosciences (NASDAQ NBIX) Stock Chart for Monday, January, 22, 2018

Loading chart…

This page was last updated on 1/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.